Finnadvance Ltd. – AKITA® 資料一覧|東京未来スタイルは研究用試薬の輸入商社です。

文献

Finnadvance社は常に、査読付きのジャーナルで研究結果を公開しています。Finnadvance社の研究チームや共同研究者の文献を以下よりご覧ください。

• Blood-brain barrier-, lung- and skin-on-chip with Tuan Nguyen et. al. BioRxiv 2023

  We are excited to announce a new research publication showcasing the capabilities of our AKITA microfluidic platform. Authored by Tuan Nguyen et al., the paper titled “Highly Scalable and Standardized Organ-on-Chip Platform with TEER for Biological Barrier Modeling” highlights the potential of AKITA in advancing vascularized biological barrier research.In collaboration with esteemed partners including Organo-Therapeutics, the University of Kuopio, and the screening facility of Helsinki University, our platform has proven to be a key tool for researchers, pharmaceutical innovators, and investors alike. The study affirms AKITA’s versatility, demonstrating its effectiveness in automation, organoid culture, and organotypic slice culture.

• Extracellular vesicles through the blood-brain barrier-on-chip with Pelin Saglam‑Metiner et. al. SCRR 2023

  The laboratory of Prof. Ozlem Yesil‑Celiktas we presented a meticulous exploration of neural/glial cell differentiation from single-origin hiPSCs—a venture that unveils a sophisticated humanized neural tissue-on-chip model, supported by the blood-brain barrier (BBB). Their extracellular vesicles derived from bone marrow mesenchymal stem cells successfully crossed the blood brain barrier, and attenuated neuro-inflammation. This scientific promises a deeper understanding of cellular dynamics and presents avenues for innovative approaches in neuroinflammation research: “Differentiation of Neurons, Astrocytes, Oligodendrocytes and Microglia From Human Induced Pluripotent Stem Cells to Form Neural Tissue‑On‑Chip: A Neuroinflammation Model to Evaluate the Therapeutic Potential of Extracellular Vesicles Derived from Mesenchymal Stem Cells”

• Cancer metastasis-on-chip modelling by Aki Manninen et al. Oncogene 2022

  Our lumen-on-chip platform was used in the recent publication in Oncogene by Professor Aki Manninen from Disease Networks at University of Oulu: “Disassembly of hemidesmosomal adhesions promotes tumorigenesis in PTEN-negative prostate cancer by targeting plectin into focal adhesions” . With Professor Manninen we demonstrated that simultaneous loss of PTEN and hemidesmosomes induced several tumorigenic properties including proliferation, migration, resistance to anoikis, apoptosis, and drug treatment in vitro, and increased metastatic capacity in vivo by using an extensive CRISPR/Cas9-mediated genetic engineering approaches in different prostate cancer cell lines combined with in vivo tumorigenesis studies in mice, bone marrow-on-chip assays and bioinformatics, as well as histological analysis of prostate cancer patient cohorts. The studies showed that these effects were driven by activation of EGFR/PI3K/Akt and FAK/Src-pathways and were abolished by plectin downregulation. Therefore, dual loss of PTEN and hemidesmosomes may have diagnostic value helping to stratify prostate cancer patients with a high risk for development of aggressive disease and highlight plectin as a potential therapeutic target in prostate cancer.

• Neurons-on-chips by Nikita Mikhailov et al. Int. J. Mol. Sci. 2022

  Data published in MDPI publication “Functional Characterization of Mechanosensitive Piezo1 Channels in Trigeminal and Somatic Nerves in a Neuron-on-Chip Model” by Nikita et al at A. I. Virtanen Institute for Molecular Sciences has shown that turbulence free microfluidic neuron-on-chip clearly differentiates trigeminal versus dorsal root ganglion neural mechanosensitivity. Finnadvance’s precision microfluidic chip fabrication demonstrated reproducibility of the results.

• Enhancing T-cell recruitment in renal cell
  carcinoma with cytokine-armed adenoviruses by Feodoroff et al. ONCOIMMUNOLOGY 2024, VOL. 13, NO. 1, 2407532

  Immunotherapy has emerged as a promising approach for cancer treatment, with oncolytic adenoviruses showing power as immunotherapeutic agents. In this study, we investigated the immunotherapeutic potential of an adenovirus construct expressing CXCL9, CXCL10, or IL-15 in clear cell renal cell carcinoma (ccRCC) tumor models. Our results demonstrated robust cytokine secretion upon viral treatment, suggesting effective transgene expression. Subsequent analysis using resistance-based transwell migration and microfluidic chip assays demonstrated increased T-cell migration in response to chemokine secretion by infected cells in both 2D and 3D cell models. …

• Human iPSC and CRISPR targeted gene knock‑in strategy for studying the somatic TIE2^L914F mutation in endothelial cells. Lazovic et. al. Angiogenesis (2024) 27:523–542

  Induced pluripotent stem cell (iPSC) derived endothelial cells (iECs) have emerged as a promising tool for studying vascular biology and providing a platform for modelling various vascular diseases, including those with genetic origins. Currently, primary ECs are the main source for disease modelling in this field. However, they are difficult to edit and have a limited lifespan. To study the effects of targeted mutations on an endogenous level, we generated and characterized an iPSC derived model for venous malformations (VMs). CRISPR-Cas9 technology was used to generate a novel human iPSC line with an amino acid substitution L914F in the TIE2 receptor, known to cause VMs. This enabled us to study the differential effects of VM causative mutations in iECs in multiple in vitro models and assess their ability to form vessels in vivo. …

ポスター

Finnadvance社や共同研究者の研究についてのAKITAのポスター・詳細情報です。

• Osteoarthritis-on-chip_Lorite Lab
• Cancer-on-Chip_Helsinki University
• Blood-brain barrier-on-chip_Lehtonen lab
• Blood vessel-on-chip_Eklund lab
• Blood vessel-on-chip_AstraZeneca
• Organoids-on-chip
• Microphysiological airway-on-chip
• Blood-brain barrier-on-chip

アプリケーションノート

お客様がより速く確実に画期的な科学的偉業を成し遂げる上でAKITAプラットフォームがどのように役立つかを、以下のプロトコルからご確認ください。

• Immune cell migration through endothelial barrier
• AKITA & Glue4Life one pager: 3D vascularization
• AKITA & Biosurfaces application note: coating-free cell scaffold
• AKITA Bone-on-Chip Application Note
• AKITA Blood-Brain-Barrier-on-Chip Application Note
• AKITA Alveolar Barrier Application Note
• AKITA Gut-on-Chip Application Note

製品情報

AKITAプラットフォームの性能と、それがお客様の研究にどう役立つかをご覧ください。Organ-on-chip生成のための複数のプロトコルや、利用可能な多数のデータにアクセスするには、(株)東京未来スタイルまでお問い合わせください。

• AKITA Plate96 Single (日本語)
• AKITA Plate96 Multi (日本語)
• AKITA TEER Lid (日本語)

• Plate96-Single – product information
• Plate96-Multi – product information
• TEER Lid – product information
• AKITA general presentation
• Frequently asked questions FAQ
• One organ-on-chip platform, many applications